×

HIV-1 mutations selected for by beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine

  • US 20040082552A1
  • Filed: 01/23/2003
  • Published: 04/29/2004
  • Est. Priority Date: 01/22/1999
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating an HIV infection in a human comprising administering an effective amount of β

  • -D-D4FC or its pharmaceutically acceptable prodrug or salt to the human, optionally in a pharmaceutically acceptable carrier, in combination or alternation with a drug that induces a mutation in HIV-1 at a location other than the 70(K to N), 90 or 172 codon of the reverse transcriptase region, and which is other than cis-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, cis-2-hydroxymethyl-5-(cytosin-1-yl)-1,3oxathiolane, 9-[4-(hydroxymethyl)-2-cyclopenten-1-yl)-guanine (carbovir), 9-[(2-hydroxyethoxy)methyl]guanine (acyclovir), interferon, 3′

    -deoxy-3′

    -azido-thymidine (AZT), 2′

    ,3′

    -dideoxyinosine (DDI), 2′

    ,3′

    -dideoxycytidine (DDC), (−

    )-2′

    -fluoro-5-methyl-β

    -L-ara-uridine (L-FMAU) or 2′

    ,3′

    -didehydro-2′

    ,3′

    -dideoxythymidine (D4T).

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×